

December 1, 2025

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Notice of Joint Research Agreement with Eurus Therapeutics Inc. for the Utilization of PPMX Antibody Library**

Perseus Proteomics Inc. (hereafter “PPMX”) and Eurus Therapeutics Inc. (hereafter “Eurus”) have today entered into a joint research agreement. This collaboration leverages the synergy between the proprietary PPMX Antibody Library 2 and Eurus’s novel genome editing technology, with the aim of developing innovative therapeutic agents.

This joint research will combine both companies’ strengths to carry out exploratory studies on new antibody candidates as well as assess the potential for novel therapeutic tools utilizing these antibodies. Depending on the progress of the screening and evaluation phases, we will consider transition to subsequent research stages.

Eurus, established in 2021, is a biotech venture possessing an original genome editing technology that does not utilize the commonly used CRISPR/Cas system (Note 1). While Eurus currently does not maintain a web presence, we have evaluated their highly unique research and development capabilities, which has led to the formation of this partnership.

As research progresses, significant developments or milestones will be disclosed as appropriate. This agreement is expected to have a minimal impact on the Company’s performance at this point.

End

Note 1: The CRISPR/Cas system is the most widely used genome editing technology to date, with its efficacy confirmed in multiple drug development pipelines and marketed therapeutics. However, safety risks arising from unintended off-target genome modifications remain a challenge, and a large number of studies are underway to address these issues.

[Eurus Therapeutics Inc. Company Overview]

Head Office: Fujisawa City, Kanagawa Prefecture

Representative Director: Takato Noumi

Founded: February 2021

Business: Development of novel gene therapies

End